January 7, 2026 By: Asa Waldstein

SARM “Research Only” Products Cited

Takeaway -

Marketing proves intended use

SARMs (selective androgen receptor modulators) are potentially dangerous, and FDA issued six SARM-related warning letters in December. Warning letters sometimes come in groups like this, which is a clear message that openly selling SARMS online will not be tolerated by FDA.

Side note: I overheard a bizarre conversation at SupplySide Global last year where a person sitting near me on some couches was loudly bragging about how many SARMs he sold online. He went on to mention that labeling “Not for human consumption” or “Research grade” allowed him to ‘get away with it.’ I was shocked and saddened. This WLW’s for you, buddy.

An interesting aspect of the letters is that FDA demonstrated that even though the products were labeled as not for human consumption, the marketing and product review showed otherwise.

From warning letter. “Despite statements on your product labeling marketing some of your products as a “RESEARCH COMPOUND” and “NOT FOR HUMAN CONSUMPTION,” evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use.”

From company website (cited in warning letter). “The Use Of Testolone Is Associated By RAD-140 Users With Dramatic Relief From Muscle Wasting Or Loss Or Muscle Tissue, Weakness, And Fatigue That Makes The Entire Otherwise-Complicated Processes Of Healing And Recovery Easy And Quick.”

Here’s an FDA warning about SARMs.

Here’s one of the recent warning letters.

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Technology & AI Innovation Committee.